BRIEF-Allogene Therapeutics Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial Planned For Early Q2 2026

Reuters01-08

BRIEF-Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial Planned For Early <a href="https://laohu8.com/S/QTWO">Q2</a> 2026

Jan 8 (Reuters) - Allogene Therapeutics Inc ALLO.O:

ALLOGENE THERAPEUTICS INC - INTERIM FUTILITY ANALYSIS OF MRD CLEARANCE FROM PHASE 2 ALPHA3 TRIAL PLANNED FOR EARLY Q2 2026
ALLOGENE THERAPEUTICS INC - PROOF-OF-CONCEPT FOR ALLO-329 SLATED BY END OF H1 2026

Source text: ID:nGNX99v5Bw

Further company coverage: ALLO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601367554?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601367554","market":"fut","top_or_hot":-1,"title":"BRIEF-Allogene Therapeutics Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial  Planned For Early Q2 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial  Planned For Early <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span>Allogene Therapeutics Inc <span>ALLO.O</span>:</p><ul><li><p>ALLOGENE THERAPEUTICS INC - INTERIM FUTILITY ANALYSIS OF MRD CLEARANCE FROM PHASE 2 ALPHA3 TRIAL  PLANNED FOR EARLY Q2 2026</p></li><li><p>ALLOGENE THERAPEUTICS INC - PROOF-OF-CONCEPT FOR ALLO-329 SLATED BY END OF H1 2026</p></li></ul><p>Source text: <span>ID:nGNX99v5Bw</span></p><p>Further company coverage: <span>ALLO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Allogene Therapeutics Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial  Planned For Early Q2 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Allogene Therapeutics Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial  Planned For Early Q2 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 21:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial  Planned For Early <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span>Allogene Therapeutics Inc <span>ALLO.O</span>:</p><ul><li><p>ALLOGENE THERAPEUTICS INC - INTERIM FUTILITY ANALYSIS OF MRD CLEARANCE FROM PHASE 2 ALPHA3 TRIAL  PLANNED FOR EARLY Q2 2026</p></li><li><p>ALLOGENE THERAPEUTICS INC - PROOF-OF-CONCEPT FOR ALLO-329 SLATED BY END OF H1 2026</p></li></ul><p>Source text: <span>ID:nGNX99v5Bw</span></p><p>Further company coverage: <span>ALLO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y9110:1","article_id":"2601367554","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601367554","pubTimestamp":1767880235,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Allogene Therapeutics Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial  Planned For Early Q2 2026Jan 8 (Reuters) - Allogene Therapeutics Inc ALLO.O:ALLOGENE THERAPEUTICS INC ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","ALLO":"Allogene Therapeutics Inc."},"translate_title":"BRIEF-Allogene Therapeutics计划于2026年第二季度初进行的2期Alpha3试验Mrd清除的中期无效性分析","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":0.9},"content_text":"BRIEF-Allogene Therapeutics Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial  Planned For Early Q2 2026Jan 8 (Reuters) - Allogene Therapeutics Inc ALLO.O:ALLOGENE THERAPEUTICS INC - INTERIM FUTILITY ANALYSIS OF MRD CLEARANCE FROM PHASE 2 ALPHA3 TRIAL  PLANNED FOR EARLY Q2 2026ALLOGENE THERAPEUTICS INC - PROOF-OF-CONCEPT FOR ALLO-329 SLATED BY END OF H1 2026Source text: ID:nGNX99v5BwFurther company coverage: ALLO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601367554","isCrawlerRequest":true}